Lipid Metabolism in Cachexia

  • Enzo Manzato
  • Giovanna Romanato


In this chapter we will review the alterations of lipoprotein metabolism observed in cachexia. Other aspects of lipid metabolism in cachexia, in particular those regarding adipose tissue, are covered in other chapters. Lipoproteins are macromolecules circulating in blood and they are quite easily measured in the clinical chemistry laboratory. For this reason lipoproteins can be used to monitor the alterations of lipid metabolism in several clinical conditions, including cachexia.


Anorexia Nervosa Lipoprotein Lipase Cholesterol Acyl Transferase Lipoprotein Lipase Activity Fatty Acid Deposition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Durrington P (2003) Dyslipidemia. Lancet 362:717–731PubMedCrossRefGoogle Scholar
  2. 2.
    Ginsberg HN, Goldberg IJ (2001) Disorders of lipoprotein metabolism. In: Braunwald E, Hauser SL, Fauci AS et al (eds) Principles of internal medicine. McGraw Hill, New York, pp 2245–2257Google Scholar
  3. 3.
    Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862–871PubMedCrossRefGoogle Scholar
  4. 4.
    Vlassara H, Spiegel RJ, San Doval D, Cerami A (1986) Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm Metabol Res 18:698–703Google Scholar
  5. 5.
    Ruge T, Svensson A, Eriksson JW et al (2001) Food deprivation increases post-heparin lipoprotein lipase activity in humans. Eur J Clin Invest 31:1040–1047PubMedCrossRefGoogle Scholar
  6. 6.
    Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91PubMedCrossRefGoogle Scholar
  7. 7.
    Nomura K, Noguchi Y, Yoshikawa T, Kondo J(1997) Plasma interleukin-6 is not a mediator of changes in lipoprotein lipase activity in cancer patients. Hepatogastroenterology 44:1519–1526PubMedGoogle Scholar
  8. 8.
    Kwong LK, Ridinger DN, Bandhauer M et al (1997) Acute dyslipoproteinemia induced by interleukin-2 lecithinxholesteryl acyltransferase, lipoprotein lipase, hepatic lipase deficiencies. J Clin Endocrinol Metab 82:1572–1581PubMedCrossRefGoogle Scholar
  9. 9.
    Hauner H, Petruschke T, Russ M et al (1995) Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 38:764–771PubMedCrossRefGoogle Scholar
  10. 10.
    Kern PA, Saghizadeh M, Ong JM et al (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111–2119PubMedCrossRefGoogle Scholar
  11. 11.
    Sethi JK, Hotamisligil GS (1999) The role of TNF-a in adipocyte metabolism. Semin Cell Dev Biol 10:19–29PubMedCrossRefGoogle Scholar
  12. 12.
    Tatidis L, Vitols S, Gruber A et al (2001) Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis. Cancer Letters 170:169–175PubMedCrossRefGoogle Scholar
  13. 13.
    Kalantar-Zadek K, Block G, Horwich T, Fonarow GC (2004) Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43:1439–1444CrossRefGoogle Scholar
  14. 14.
    Grunfeld C, Pang M, Doerrler W et al (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:1045–1052PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Enzo Manzato
    • 1
  • Giovanna Romanato
    • 1
  1. 1.Department of Medical and Surgical SciencesUniversity of PaduaPaduaItaly

Personalised recommendations